Emil Kakkis Insider Profile

4 Followers
Emil Kakkis, President & CEO, Director at Ultragenyx Pharmaceutical, holds 2.79M shares in Ultragenyx Pharmaceutical (Ticker: RARE), holds 44.27K shares in BioMarin Pharmaceutical (Ticker: BMRN). Most recently, Emil Kakkis Sold ― shares of Ultragenyx Pharmaceutical on Sep 05, 2024 for an estimated value of 1.12M.
tipranks
Emil Kakkis

Emil Kakkis
Ultragenyx Pharmaceutical (RARE)
President & CEO, Director

Ranked #3,251 out of 99,218 Corporate Insiders

Profitable Transactions

71%
5 out of 7 Profitable Transactions

Average Return

+60.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$148M
98.03%
1.97%
A breakdown of Emil Kakkis's holdings

Insider Roles

Ultragenyx Pharmaceutical
(RARE)
President & CEO, Director
BioMarin Pharmaceutical
(BMRN)
CMO
Roles that Emil Kakkis holds in companies

Most Profitable Insider Trade

Stock:
Ultragenyx Pharmaceutical
(RARE)
Rating:Informative Buy
Date:Mar 13, 2020 - Mar 13, 2021
Return:+192.90%
The most profitable trade made by Emil Kakkis

Emil Kakkis's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Ultragenyx Pharmaceutical
Sep 05, 2024
President & CEO, Director
Informative Sell
1.12M
$145.51M
BioMarin Pharmaceutical
Mar 04, 2009
CMO
Uninformative Sell
92.39K
$2.92M
List of latest transactions for each holding click on a transaction to see Emil Kakkis's performance on stock

Emil Kakkis insider profile FAQ

What is the percentage of profitable transactions made by Emil Kakkis?
The percentage of profitable transactions made by Emil Kakkis is 71%.
    What is the average return per transaction made by Emil Kakkis?
    The average return per transaction made by Emil Kakkis is 60.30%.
      What stocks does Emil Kakkis hold?
      Emil Kakkis holds: RARE, BMRN stocks.
        What was Emil Kakkis’s latest transaction?
        Emil Kakkis latest transaction was an Informative Sell of $1.12M.
          What was Emil Kakkis's most profitable transaction?
          Emil Kakkis’s most profitable transaction was an Informative Buy of RARE stock on March 13, 2020. The return on the trade was 192.90%.
            What is Emil Kakkis's role in Ultragenyx Pharmaceutical?
            Emil Kakkis's role in Ultragenyx Pharmaceutical is President & CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.